Mabion
  • Company
    • About us
      • History
      • Leaderships
      • Team
      • EU grants
      • Requests for Proposal
      • Sustainability – ESG
      • Bussines strategy
      • Quality policy
      • Virtual Tour
    • Investors
      • Corporate documents
      • Shareholders and shares
      • Periodic reports
      • Current reports
      • Sustainability reports
      • Corporate governance at Mabion
      • Financial data
      • For Investors
      • Calendar
  • Resources
    • Science Hub
    • Press releases
    • News
    • Events
    • Media kit
  • Services
    • Process Development
    • Analytics 
    • Drug Substance Manufacturing
  • Contact
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • Science News
  • Resources

Virus

Microscopia electronica de Hantavirus - Centers for Disease Control and Prevention

Hantavirus Vaccine Research in Light of 2026 Cases

2026-05-11

Are mucosal vaccines the future of COVID-19 prevention?

2024-09-12
JN.1 variant of SARS-CoV-2 virus.

COVID-19 vaccine for 2024/25 season will target JN.1 variant

2024-05-14
Vaccine and syringe injection for prevention, immunization and treatment of coronavirus infection (COVID-19, nCoV 2019)

Effectiveness of 2023-24 season COVID vaccines: First estimates are in

2024-02-14

Moderna succeeds in the pivotal trial of RSV vaccine

2024-01-03

A new affordable HPV vaccine will help fight cervical cancer

2023-12-18

Researchers infect human volunteers with Zika virus in a quest for effective vaccine

2023-12-13

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • CDMO
    • Media kit
    • Press releases
    • Events

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. HTML Sitemap

    Powered by

    Veneo